BioSpace News Archive

Kintara Therapeutics, Inc. (formerly DelMar Pharmaceuticals, Inc.) (“Kintara” or the “Company”) (Nasdaq: KTRA) announced today that it has entered into definitive agreements with investors providing for the sale and issuance of up to 2,435 shares of its Series C Convertible Preferred Stock (the “Preferred Stock”) at a purchase price of

New Model Predicts Where and When Seasonal Sickness Will Hit Hardest and Helps Get Communication, Care and Relief There Sooner

The Personalized Medicine Coalition is pleased to release a new patient-centered research agenda for personalized medicine that defines 45 research questions for the field across nine areas of special concern for patients themselves.

A presentation by the Nordic Nanovector’s senior management team will take place the same day at 8:30 am CEST at: Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo, Meeting Room: Vika Auditorium. The presentation will be a live webcast, and a recording will then be available at www.nordicnanovector.com in the section: Invest

Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax ® personalized immune therapies for solid tumor cancers, today announced that the Company has completed a non-dilutive debt financing for ne

Lawrence A. Rosen appointed by Supervisory Board as new Chairman with immediate effect Appointment comes after Dr. Håkan Björklund decided to step down as Chairman of the Supervisory Board and as a Supervisory Board member VENLO, The Netherlands--( BUSINESS WIRE )-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced today a transition in the leadership of its Supervisory Board after an extraordinary meeting of

Three Chesapeake Urology physicians and their teams have been designated as Axonics Centers of Excellence by Axonics Modulation Technologies, Inc. The designation recognizes Andrew Shapiro , M.D., Lisa Hawes , M.D., and

Tosk, Inc.’s recent success in its Phase 2a, placebo-controlled, clinical study of TK-90 in head and neck cancer patients, validates the effectiveness of the company’s use of fruit flies as a powerful discovery tool in its research, according to Vice President of Research and Development, Bill Garland.

Tosk, Inc. announced today that its patented drug, TK-90, which prevents the adverse side effects of frontline cancer therapies, succeeded in human clinical studies involving 25 head-and-neck cancer patients.

Ultimovacs ASA, a pharmaceutical company developing novel immunotherapies against cancer, announces its second quarter 2020 results